Skip to main content
. Author manuscript; available in PMC: 2021 Aug 10.
Published in final edited form as: Vaccine. 2020 Jul 17;38(36):5803–5813. doi: 10.1016/j.vaccine.2020.06.049

Figure 2. LLOT binds to host cells.

Figure 2.

Control HeLa cells (A), and HeLa cells pre-treated with 5 mM methly-β-cyclodextrin (mβCD) (B), were incubated 10 min at 4°C with LLO or LLOT. (C) HeLa cells pre-treated, or not, with 5 mM mβCD were incubated 10 min at 4°C with LLO D1–3. (D) THP-1 cells were incubated 10 min at 4°C with LLO or LLOT. (A, B, C, D) After incubation at 4°C, cells were washed and lysed at 4°C, and cell lysates were analyzed by immunoblotting using anti-LLO and anti-actin primary antibodies. Representative immunoblots were selected from at least 3 independent experiments.